Levels of interleukin-2 (IL-2), a cytokine that binds to specific receptors expressed on T-cells and natural killer cells and thereby mediates their immune-stimulating effects, have been seen to correlate with long term survival in SCLC patients13. This evidence concerns the gene IL2 and small cell lung carcinoma.